Yves Jacob

🤩 Delighted to share that, today, the European Medicines Agency has granted approval to Servier’s first targeted therapy for patients with glioma.  ✅ This approval is based on robust clinical data, demonstrating a significant step forward in the treatment of a rare brain cancer.  ✅ It’s also a strong recognition of our scientific capabilities and the unfailing work of our R&D teams, who are committed to advancing precision medicine in oncology.  Proud to see our research contribute to transforming patient outcomes.  #Oncology #Glioma #RnD #WeAreServier 

692

33 commentaires

Teva at Morgan Stanley: From Generics Giant to Biopharma Growth Story   Yesterday at the Morgan Stanley Global Healthcare Conference, Teva’s CEO Richard Francis gave a clear signal: the Teva of today is no longer the Teva of five years ago.   Highlights from the discussion:   -      10 consecutive quarters of growth under the Pivot to Growth strategy.   -      AUSTEDO tracking to >$3bn by 2027, despite IRA headwinds.   -      Schizophrenia franchise (UZEDY + long-acting olanzapine) → covers ~75% of patients, with >90% gross margins.   -      Duvakitug (TL1A asset, partnered with Sanofi): Phase II data suggests best-in-class potential in Crohn’s & UC, with multiple new indications planned. LOE only in 2042.   -      Generics repositioned: cash engine and “venture capital arm” for innovation. Biosimilars (25+ assets) and GLP-1 generics add optionality.   -      Capital allocation discipline: derisked BD, partnerships to avoid heavy CapEx, focus on shareholder value.   Strategic insight:   Teva is repositioning itself as a biopharma growth company with a pipeline of $11–13bn in peak sales potential. Teva’s innovative assets operate at gross margins above 90%, compared with a company average of 54%. As these assets scale, the economics of Teva’s P&L fundamentally change.   The generics legacy remains important but no longer defines the narrative. Instead, it funds the transformation.   Bottom line: Teva is executing a rare and credible shift: from survival mode to growth mode, from generics to innovation. 🔔 Follow for insights ♻️ Share if you find it interesting   #teva #generics #strategy #transformation

336

8 commentaires

We are incredibly proud to support French innovation and entrepreneurship with our partnership with Juisci, a promising startup that just raised €5.5M! 💡   At Laboratoires Pierre Fabre, we are constantly exploring innovative ways to deliver high-quality medical education to healthcare professionals. By working with Juisci, particularly in the field of oncology, we are helping equip doctors with the most up-to-date medical knowledge for them to provide the best possible care to their patients.   This collaboration will extend to the upcoming #ESMO25 Congress, a key event for advancing knowledge in oncology. Together with Juisci, we aim to continue pushing boundaries in supporting healthcare providers.   Because ensuring excellence in patient care starts with empowering those who care for them.   #NewWaysToCare #jechoisilafrenchtech #oncology #medicaleducation #patientcare #digital

90

3 commentaires